Cargando…

Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer

We demonstrated the presence of PIK3CA major mutations of cfDNA could be discriminatory predictor of RFS and BCSS in early‐stage TNBC patients which may be associated with PI3K pathway dependent AR phosphorylation.

Detalles Bibliográficos
Autores principales:	Takeshita, Takashi, Yamamoto, Yutaka, Yamamoto‐Ibusuki, Mutsuko, Inao, Toko, Sueta, Aiko, Fujiwara, Saori, Omoto, Yoko, Iwase, Hirotaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714688/ https://www.ncbi.nlm.nih.gov/pubmed/26353837 http://dx.doi.org/10.1111/cas.12813

Ejemplares similares

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer
por: Suyama, Koichi, et al.
Publicado: (2017)

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
por: Sueta, Aiko, et al.
Publicado: (2014)

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2018)

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
por: Omoto, Yoko, et al.
Publicado: (2015)

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer
por: Tomiguchi, Mai, et al.
Publicado: (2016)

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence
por: Sueta, Aiko, et al.
Publicado: (2017)

A progressive and refractory case of breast cancer with Cowden syndrome
por: Sueta, Aiko, et al.
Publicado: (2022)

PTIP Associated protein 1, PA1, Is an Independent Prognostic Factor for Lymphnode Negative Breast Cancer
por: Takeshita, Takashi, et al.
Publicado: (2013)

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer
por: Fujiwara, Saori, et al.
Publicado: (2014)

APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer
por: Fujiki, Yoshitaka, et al.
Publicado: (2018)

A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer
por: Yamamoto, Satoko, et al.
Publicado: (2013)

Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer
por: Hayashi, Mitsuhiro, et al.
Publicado: (2015)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
por: Kosaka, Yoshimasa, et al.
Publicado: (2020)

The role of exosomal microRNAs; focus on clinical applications in breast cancer
por: Sueta, Aiko, et al.
Publicado: (2019)

The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer
por: Shiota, Takuya, et al.
Publicado: (2016)

Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study
por: Iwase, H, et al.
Publicado: (2013)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival
por: Rezano, Andri, et al.
Publicado: (2013)

High density of CD204‐positive macrophages predicts worse clinical prognosis in patients with breast cancer
por: Miyasato, Yuko, et al.
Publicado: (2017)

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
por: Cossu-Rocca, Paolo, et al.
Publicado: (2015)

Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion
por: Okumura, Yasuhiro, et al.
Publicado: (2008)

Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects
por: Omoto, Yoko, et al.
Publicado: (2015)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers
por: Jacot, William, et al.
Publicado: (2015)

GANP protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development
por: Kuwahara, Kazuhiko, et al.
Publicado: (2016)

PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report
por: Valencia, Guillermo Arturo, et al.
Publicado: (2021)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer
por: Jouali, Farah, et al.
Publicado: (2018)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression
por: Pesch, Andrea M., et al.
Publicado: (2022)

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
por: Lehmann, Brian D, et al.
Publicado: (2014)

Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)

Mutations in PIK3CA are infrequent in neuroblastoma
por: Dam, Vincent, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_njedce7qjeb5q61obb1ikttv87